Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Short-term Investments (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Short-term Investments for 10 consecutive years, with $133.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Short-term Investments fell 35.65% to $133.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $133.9 million, a 35.65% decrease, with the full-year FY2025 number at $133.9 million, down 35.65% from a year prior.
  • Short-term Investments was $133.9 million for Q4 2025 at Iovance Biotherapeutics, down from $142.7 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $222.0 million in Q1 2024 to a low of $20.9 million in Q2 2023.
  • A 3-year average of $142.6 million and a median of $153.8 million in 2023 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: skyrocketed 168.12% in 2024, then plummeted 35.65% in 2025.
  • Iovance Biotherapeutics' Short-term Investments stood at $165.0 million in 2023, then rose by 26.13% to $208.1 million in 2024, then crashed by 35.65% to $133.9 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Short-term Investments are $133.9 million (Q4 2025), $142.7 million (Q3 2025), and $168.7 million (Q2 2025).